Tagrisso Osimertinib Film-Coated Tablets 80mg

Send Inquiry

Request To Call Back

Tagrisso Osimertinib Film-Coated Tablets 80mg

Get a Price/Quote

MOQ : 50 Boxes

Tagrisso Osimertinib Film-Coated Tablets 80mg Specification

Packaging Type
Box with blister strips

Dosage Form
Film-coated tablet

Origin of Medicine
Pharmaceutical

Pacakaging (Quantity Per Box)
30 tablets per box

Salt Composition
Osimertinib (as mesylate)

Indication
Treatment of metastatic or locally advanced non-small cell lung cancer (NSCLC) with EGFR T790M mutation

Life Span
Refer to expiry date on packaging (typically 2-3 years from manufacture)

Drug Type
Antineoplastic agent

Ingredients
Osimertinib

Physical Form
Film-coated tablet

Function
Targeted therapy for treatment of EGFR-mutated NSCLC

Recommended For
Patients with non-small cell lung cancer (NSCLC) with specific EGFR mutations

Dosage
80 mg once daily or as directed by a physician

Dosage Guidelines
Take orally, with or without food

Suitable For
Adults

Quantity
30 tablets per box

Storage Instructions
Store below 30C, in the original package to protect from moisture

Prescription Required
Yes

Route of Administration
Oral

Appearance
Pink, round, film-coated tablet

Regulatory Status
Schedule H prescription drug

Contraindications
Known hypersensitivity to osimertinib or any excipients

Usage
As prescribed for EGFR mutation-positive NSCLC

Pregnancy Category
Consult physician; not recommended during pregnancy

Strength
80 mg per tablet

Side Effects
Diarrhea, rash, dry skin, nail toxicity, decreased appetite, possible QT prolongation

Tagrisso Osimertinib Film-Coated Tablets 80mg Trade Information

Minimum Order Quantity
50 Boxes

Payment Terms
Cash in Advance (CID)

Supply Ability
1000 Boxes Per Month

Delivery Time
2-5 Days

Main Domestic Market
All India

About Tagrisso Osimertinib Film-Coated Tablets 80mg

Tagrisso Osimertinib Film-Coated Tablets 80mg offer transcendent access to cutting-edge, targeted therapy for EGFR mutation-positive non-small cell lung cancer (NSCLC). Each prodigious pink, round, film-coated tablet contains 80mg of invincible osimertinib, formulated for reduced side effects and advanced efficacy. Carefully engineered for oral administration, it delivers reliable results for patients seeking trending solutions. This schedule H prescription drug is designed for adults, providing a selective approach for those with specific EGFR mutations. Usage should strictly follow physician guidance. Store below 30C, protected from moisture.

Versatile Applications and Innovative Features

Tagrisso Osimertinib Film-Coated Tablets 80mg are primarily indicated for adult patients with advanced or metastatic NSCLC harboring EGFR T790M mutations. Its material feature includes a specialized film-coating for ease of swallowing and stability, ensuring consistent dosing. Application method is simple-take one tablet orally, with or without food, as prescribed. The prodigious formulation is suitable for long-term cancer management under specialist supervision, and its robustness is tailored to meet the unique needs of oncology therapy.

Sample, Supply, and Efficient Dispatch

Tagrisso Osimertinib Film-Coated Tablets 80mg samples are available for hospital and clinical valuation upon request. With a high supply ability across the main domestic markets in India, express shipping and meticulous packing & dispatch protocols are followed for prompt delivery. Each pack contains 30 tablets, ensuring continuous therapy. Pharmaceutical integrity is maintained from packing to dispatch, allowing healthcare providers expedited access and patients uninterrupted treatment cycles for optimal care.

FAQ's of Tagrisso Osimertinib Film-Coated Tablets 80mg:

Q: How should Tagrisso Osimertinib Film-Coated Tablets 80mg be taken?

A: Tagrisso should be taken orally, once daily with or without food, exactly as prescribed by your healthcare provider. Do not alter the dose unless instructed by a physician.

Q: What are the main contraindications for using Tagrisso Osimertinib?

A: Tagrisso is contraindicated in patients with known hypersensitivity to osimertinib or any of its excipients. Consult your physician to confirm suitability.

Q: What side effects can occur while using this medication?

A: Common side effects of Tagrisso include diarrhea, rash, dry skin, nail toxicity, decreased appetite, and potential QT interval prolongation. Inform your physician if side effects persist or worsen.

Q: Where should Tagrisso Osimertinib be stored?

A: Store the tablets below 30C in the original packaging to protect from moisture and maintain potency until the expiry date indicated on the box.

Q: What is the main benefit of using Tagrisso for NSCLC patients?

A: Tagrisso offers targeted, advanced therapy specifically for patients with EGFR mutation-positive NSCLC, with reduced toxicity compared to traditional treatments, helping improve outcomes.

Q: When is samples availability and express shipping provided?

A: Samples are available for clinical evaluation upon request. Express shipping, along with robust packing and dispatch protocols, ensures timely delivery to main domestic markets.

Tell us about your requirement

Price:

Quantity

Select Unit

50
100
200
250
500
1000+

Additional detail

Mobile number

More Products in Oncology And Targeted Cancer Therapies Medication Category

Iclusig Ponatinib Film-Coated Tablets 15mg

Minimum Order Quantity : 50 Boxes

Drug Type : Other, Antineoplastic (anticancer) agent

Indication : Indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosomepositive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior tyrosine kinase inhibitor therapy

Dosage : As directed by physician, typically 15 mg once daily

Life Span : Refer to expiry date on packaging

Storage Instructions : Store below 30C, in a dry place, protected from light

Get a Price/Quote

Iclusig Ponatinib Tablets 45mg

Minimum Order Quantity : 50 Strips

Drug Type : Other, Prescription only (Rx)

Indication : Indicated for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

Dosage : 45 mg per tablet, as directed by healthcare provider

Life Span : See packaging for expiry date

Storage Instructions : Store at room temperature, keep in original packaging, away from moisture and heat

Get a Price/Quote